Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
NCT03522545
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Treatment-resistant Bipolar Depression
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- The University of Texas Health Science Center, Houston
- Last updated on ClinicalTrials.gov
- June 22, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- The University of Texas Health Science Center at Houston · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.